Miguel Sanmamed

Miguel Sanmamed, MD, PhD, is an Adjunct Assistant Professor in the Department of Medical Oncology and Hematology at the Yale School of Medicine. His research focuses on cancer immunotherapy, tumor microenvironment dynamics, and translational clinical trials targeting immunomodulatory pathways. Dr. Sanmamed holds a PhD from Oviedo University (2011) and an MD from Santiago de Compostela University (2005). His work bridges basic immunology with clinical applications, particularly in developing novel therapies for solid tumors and hematologic malignancies.

Key research areas include T-cell biology, tumor-infiltrating lymphocytes (TILs), checkpoint inhibitors, and combination therapies. He collaborates with leading institutions on Phase I/II trials evaluating T-cell engagers, immunocytokines, and personalized mRNA vaccines. Recent studies highlight innovative approaches such as CD25 Treg depletion (RG6292) and FAP-targeted IL-2 variants.

Publications emphasize mechanistic insights into immunotherapy resistance, biomarker development, and preclinical models like humanized mice. His work frequently appears in high-impact journals such as Nature Reviews Clinical Oncology and Cancer Discovery.